Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation disease BEFREE Our data suggest that PMAs are hypermetabolic on PET, have elevated PIs and BRAF V600E mutations, and behave aggressively. 26886222 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation disease BEFREE We report a patient with a BRAF V600E mutated pilomyxoid astrocytoma who failed multiple conventional chemotherapy regimens. 24821190 2014
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 Biomarker disease BEFREE Polymerase chain reaction testing identified KIAA1549:BRAF fusions in 51 (48%) tumors overall, including 42 (60%) pilocytic astrocytomas, 4 (17%) unclassifiable low-grade gliomas, 4 (36%) low-grade glioneuronal/neuroepithelial tumors, 0 (of 5) pleomorphic xanthoastrocytomas, 0 (of 4) diffuse astrocytomas (World Health Organization grade II), and 1 (of 3, 33%) pilomyxoid astrocytoma. 22157620 2012
Entrez Id: 10643
Gene Symbol: IGF2BP3
IGF2BP3
0.020 Biomarker disease BEFREE Genes overexpressed in PMA vs. PA, ranked according to fold-change, included developmental genes H19, DACT2, extracellular matrix collagens (COL2A1; COL1A1) and IGF2BP3 (IMP3), the latter previously identified as an adverse prognostic factor in PMA and PA. 25521223 2015
Entrez Id: 10643
Gene Symbol: IGF2BP3
IGF2BP3
0.020 AlteredExpression disease BEFREE Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma. 23584203 2013
Entrez Id: 57670
Gene Symbol: KIAA1549
KIAA1549
0.010 Biomarker disease BEFREE With the exception of BRAF:KIAA1549 and pilocytic/pilomyxoid astrocytoma morphology, and possibly QKI-MYB and angiocentric glioma, there was not a strong correlation between histological features/tumor subtype and the specific fusion. 31595628 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.010 GeneticVariation disease BEFREE H3K27M mutation occurs exclusively in pHGGs arising from the midline and presents with varied histomorphological features ranging from low-grade pilomyxoid astrocytoma to highly pleomorphic glioblastoma along with ATRX loss and p53 mutations. 29063957 2018
Entrez Id: 546
Gene Symbol: ATRX
ATRX
0.010 GeneticVariation disease BEFREE H3K27M mutation occurs exclusively in pHGGs arising from the midline and presents with varied histomorphological features ranging from low-grade pilomyxoid astrocytoma to highly pleomorphic glioblastoma along with ATRX loss and p53 mutations. 29063957 2018
Entrez Id: 1277
Gene Symbol: COL1A1
COL1A1
0.010 Biomarker disease BEFREE Genes overexpressed in PMA vs. PA, ranked according to fold-change, included developmental genes H19, DACT2, extracellular matrix collagens (COL2A1; COL1A1) and IGF2BP3 (IMP3), the latter previously identified as an adverse prognostic factor in PMA and PA. 25521223 2015
Entrez Id: 1280
Gene Symbol: COL2A1
COL2A1
0.010 Biomarker disease BEFREE Genes overexpressed in PMA vs. PA, ranked according to fold-change, included developmental genes H19, DACT2, extracellular matrix collagens (COL2A1; COL1A1) and IGF2BP3 (IMP3), the latter previously identified as an adverse prognostic factor in PMA and PA. 25521223 2015
Entrez Id: 5781
Gene Symbol: PTPN11
PTPN11
0.010 GeneticVariation disease BEFREE We present here a patient with NS with a PTPN11 mutation and an optic pathway pilomyxoid astrocytoma. 25585602 2015
Entrez Id: 168002
Gene Symbol: DACT2
DACT2
0.010 Biomarker disease BEFREE Genes overexpressed in PMA vs. PA, ranked according to fold-change, included developmental genes H19, DACT2, extracellular matrix collagens (COL2A1; COL1A1) and IGF2BP3 (IMP3), the latter previously identified as an adverse prognostic factor in PMA and PA. 25521223 2015
Entrez Id: 613
Gene Symbol: BCR
BCR
0.010 Biomarker disease BEFREE BCR gene disruption in a pilomyxoid astrocytoma. 17080723 2006